LEADER 01989nam  2200553 a 450 
001 9910823624703321
005 20200520144314.0
010   $a1-61761-033-X
035   $a(CKB)2560000000069708
035   $a(EBL)3020832
035   $a(SSID)ssj0000469914
035   $a(PQKBManifestationID)11307598
035   $a(PQKBTitleCode)TC0000469914
035   $a(PQKBWorkID)10531711
035   $a(PQKB)11462117
035   $a(MiAaPQ)EBC3020832
035   $a(Au-PeEL)EBL3020832
035   $a(CaPaEBR)ebr10680970
035   $a(OCoLC)923664535
035   $a(EXLCZ)992560000000069708
100   $a20100617d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aHepatitis C infection in dialysis$b[electronic resource] /$fMagid A. Fahim and David W. Johnson
210   $aNew York $cNova Biomedical Books/Novinka$dc2010
215   $a1 online resource (58 p.)
225 1 $aNephrology research and clinical developments
300   $aDescription based upon print version of record.
311   $a1-61728-851-9 
320   $aIncludes bibliographical references (p. [35]-41) and index.
327   $aEpidemiology -- Risk factors for HCV acquisition in haemodialysis patients -- Prevention of HCV transmission in haemodialysis units -- Diagnosis, screening, and evaluation -- Hepatic pathology and complications -- Treatment and monitoring -- Outcomes.
410  0$aNephrology research and clinical developments series.
606   $aHepatitis C
606   $aHemodialysis$xComplications
615  0$aHepatitis C.
615  0$aHemodialysis$xComplications.
676   $a616.3/623
700   $aFahim$b Magid A$01686816
701   $aJohnson$b David W$g(David Wayne),$f1964-$01686817
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910823624703321
996   $aHepatitis C infection in dialysis$94059854
997   $aUNINA